FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1378-1380 March 29, 2007 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kahn, S. E. PubMed Citation

To the Editor: Kahn et al. (Dec. 7 issue)¹ report on A Diabetes Outcome Progression Trial (ADOPT), which assessed the glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. It is difficult to maintain target levels of glycated hemoglobin with the use of traditional oral antidiabetic drugs, owing to declining -cell function.² In ADOPT, the annual increase in glycated hemoglobin levels over a 4-year period in patients with newly diagnosed diabetes was greatest with glyburide, intermediate with metformin, and least with rosiglitazone. Our longitudinal data (for 2005–2006) from a nationwide general-practitioner database in Germany (Disease Analyzer)^3,4 indicate similar findings. Among 12,304 . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.